Modeling economic evaluations of pharmaceuticals: Manipulation or valuable tool?

Clinical Therapeutics

Volumn 21, Issue 5, 1999, Pages 896-908

  Khan, Zeba M ^a   Miller, David W ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Clinical trials; Economic evaluations; Economic modeling; Health care; Modeling

Indexed keywords

CLINICAL RESEARCH; COST BENEFIT ANALYSIS; DRUG RESEARCH; HEALTH CARE COST; HEALTH CARE PLANNING; REVIEW;

EID: 0033045356     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(99)80011-3     Document Type: Article

References (41)

1. 1. Morris S. A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy. Health Econ. 1997;6:589-601.
2. 2. Sheldon TA. Problems of using modelling in the economic evaluation of health care. Health Econ. 1996;5:1-11.
3. 3. Kassirer JP, Angell M. The journal's policy on cost-effectiveness analysis. NEJM. 1994;331:669-670. Editorial.
4. 4. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996;313:275-283.
5. 5. Halpern MT, Luce BR, Brown RE, et al. Health and economic outcomes modeling practices: A suggested framework. Value Health. 1998;1:131-147.
6. 6. Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation; An unavoidable fact of life. Health Econ. 1997;6:217-227.
7. 7. Jonsson B, Johannesson M, Kjekshurst J, et al. Cost-effectiveness of cholesterol-lowering: Results from the Scandinavian Simvastatin Survival Study. Eur Heart J. 1996;17:1001-1007.
8. 8. Freedberg KA, Hardy DW, Holzman RS, et al. Validating literature-based models with direct clinical trial results: The cost-effectiveness of secondary prophylaxis for PCP in AIDS patients. Med Decis Mak, 1996;16:29-35.
9. 9. Drummond MF. The future of pharmacoeconomics: Bridging science and practice. Clin Ther. 1996;18:969-978.
10. 10. Drummond MF, Bloom BS, Carrin G, et al. Issues in the cross-national assessment of health technology. Int J Technol Assess Health Care. 1992;8:671-682.
11. 11. Schoenbaum SC, McNeil BJ, Kavet J. The swine-influenza decision. NEJM. 1976; 295:759-765.
12. 12. Sculpher M, Drummond M, Buxton M. Economic evaluation in health care research and development: Undertake it early and often. Uxbridge, UK: Brunel University; 1995. HERG Discussion Paper No. 12.
13. 13. Cohen DJ, Breall JA, Ho KK, et al. Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision analytic model. Circulation. 1994; 89:1859-1874.
14. 14. Luce BR. Policy implications of modeling the cost-effectiveness of health care technologies. Drug Inf J. 1995;29:1469-1475.
15. 15. Stason W, Weinstein M. Allocation of resources to manage hypertension. NEJM. 1977;296:732-739.
16. 16. Weinstein M, Stason W. Foundation of cost-effectiveness analysis for health and medical practices. NEJM. 1977;296:716-721.
17. 17. Office of Technology Assessment. Update of Federal Activities Regarding the Use of Pneumococcal Vaccine. Washington, DC: US Government Printing Office; 1994.
18. 18. Willems J, Sanders C, Riddough M. Cost-effectiveness of vaccination against pneumococcal pneumonia. NEJM. 1980;303: 553-559.
19. 19. Eddy D. Screening of Cancer: Theory, Analysis, and Design. Englewood Cliffs, NJ: Prentice Hall; 1980.
20. 20. Fiore M, Novotny T, Pierce J, et al, Methods used to quit smoking in the United States: Do cessation programs help? JAMA. 1990;263:2760-2765.
21. 21. Public Health Focus: Effectiveness of smoking control strategies. MMWR Morb Mortal Wkly Rep. 1992;41:645-647, 653.
22. 22. Rosenquist CJ, Lindfors KK. Screening mammography in women aged 40-49 years: Analysis of cost-effectiveness. Radiology. 1994;191:647-650.
23. 23. Elixhauser A, Weschler JM, Kitzmiller JL, et al. Cost-benefit analysis of preconception care for women with established diabetes mellitus. Diabetes Care. 1993;16: 1146-1157.
24. 24. Teo KK, Yusuf S, Collins R, et al. Effects of intravenous magnesium in suspected acute myocardial infarction: Overview of randomized trials. BMJ. 1991;303:1499-1503.
25. 25. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomized factorial trial assessing early oral captopril, oral mononitrate and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction, Lancet. 1995;345:669-685.
26. 26. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic HIV virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. NEJM. 1990; 322:941-949.
27. 27. Aboulker JP, Swart AM. Preliminary analysis of the Concorde trial. Lancet. 1993;341:889-890.
28. 28. Johannesson M, Jonsson B. Economic evaluation of osteoporosis prevention. Health Policy. 1993;24:103-124.
29. 29. Horwitz RI, Feinstein AR. Improved observational method for studying therapeutic efficacy: Suggestive evidence that lidocaine prophylaxis prevents death in acute myocardial infarction. JAMA. 1981; 246:2455-2459.
30. 30. Hine LK, Laird N, Hewitt P, et al. Meta-analytic evidence against the prophylactic use of lidocaine in acute myocardial infarction. Arch Intern Med. 1989;149:2694-2698.
31. 31. Hillman AL, Eisenberg JM, Pauly M, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. NEJM. 1991;324:1362-1365.
32. 32. Thornton JG. Decision analysis in obstetrics and gynaecology. Bailliere's Clin Obstet Gynaecol. 1990;4:857-866.
33. 33. Economic analysis of health care technology. A report on principles. Task Force on Principles for Economic Analysis of Health Care Technology. Ann Intern Med. 1995;123:61-70.
34. 34. Mason J, Drummond M. Reporting guidelines for economic studies. Health Econ. 1995;4:85-94.
35. 35. US Food and Drug Administration. Principles for the Review of Pharmacoeconomic Promotion. Rockville, Md: Food and Drug Administration; 1995. Draft.
36. 36. Weinstein MD, Siegel JE, Gold MR, et al. Recommendation of the Panel of Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1253-1258.
37. 37. Kannell WB, Woolf PA, Garrison RJ, eds. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Bethesda, Md: US Public Health Service; 1987. Publication NIH 87-2703.
38. 38. West of Scotland Coronary Prevention Study Group. A coronary primary prevention study of Scottish men aged 45-65 years trial design. J Clin Epidemiol 1992; 45:849-860.
39. 39. Glick H, Kinosian B, Schulman K. Decision analytic modelling: Some uses in the evaluation of new pharmaceuticals. Drug Inf J. 1994;28:691-707.
40. 40. Briggs AH, Sculpher MJ, Buxton MJ. Uncertainty in economic evaluation of health care technologies: The role of sensitivity analysis. Health Econ. 1994;308:283-284.
41. 41. Simpson KN. Problems and perspectives on the use of decision-analysis models for prostate cancer. J Urol. 1994;152(5 pt 2): 1888-1893.